Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Fosfomycin-Overcoming Problematic In Vitro Susceptibility Testing and Tricky Result Interpretation: Comparison of Three Fosfomycin Susceptibility Testing Methods

J. Závora, G. Kroneislová, M. Kroneisl, V. Adámková

. 2024 ; 13 (11) : . [pub] 20241105

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25002200

Grantová podpora
MH CZ - DRO - VFN00064165 Ministry of Health, Czech Republic

Background: Fosfomycin (FOS) is an older antimicrobial agent newly rediscovered as a possible treatment for infections with limited therapeutic options (e.g., Gram-negative bacteria with difficult-to-treat resistance, DTR), especially in intravenous form. However, for correct usage of FOS, it is necessary to have a reliable susceptibility testing method suitable for routine practice and robust interpretation criteria. Results: The results were interpreted according to 2023 interpretation criteria provided by the European Committee on Antimicrobial Susceptibility Testing (EUCAST). DTR Gram-negatives were more likely to be resistant to FOS (45% in Enterobacterales and 20% in P. aeruginosa) than non-DTR (10% and 6.7%, resp.). All isolates of S. aureus were susceptible to FOS. In Gram-negatives, all agreement values were unacceptable. Etest® performed better in the DTR cohort (categorical agreement, CA, 80%) than in the non-DTR cohort (CA 45.7%). There were no very major errors (VREs) observed in P. aeruginosa. S. aureus had surprisingly low essential agreement (EA) rates (53% for MRSA and 47% for MSSA) for Etest®, but categorical agreement was 100%. Methods: A total of 130 bacterial isolates were tested and compared using the disc diffusion method (DD) and gradient strip method (Etest®) with the reference method (agar dilution, AD). The spectrum of isolates tested was as follows: 40 Enterobacterales (20 DTR vs. 20 non-DTR), 30 Pseudomonas aeruginosa (15 DTR vs. 15 non-DTR), and 60 Staphylococcus aureus (30 methicillin-susceptible, MSSA, vs. 30 methicillin-resistant, MRSA). Conclusions: Neither one of the tested methods was identified as a suitable alternative to AD. It would be beneficial to define more interpretation criteria, at least in some instances.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002200
003      
CZ-PrNML
005      
20250123102021.0
007      
ta
008      
250117s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/antibiotics13111049 $2 doi
035    __
$a (PubMed)39596744
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Závora, Jan $u Clinical Microbiology and ATB Centre, General University Hospital, 128 08 Prague, Czech Republic $u Department of Medical Microbiology, Palacky University, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000262386514
245    10
$a Fosfomycin-Overcoming Problematic In Vitro Susceptibility Testing and Tricky Result Interpretation: Comparison of Three Fosfomycin Susceptibility Testing Methods / $c J. Závora, G. Kroneislová, M. Kroneisl, V. Adámková
520    9_
$a Background: Fosfomycin (FOS) is an older antimicrobial agent newly rediscovered as a possible treatment for infections with limited therapeutic options (e.g., Gram-negative bacteria with difficult-to-treat resistance, DTR), especially in intravenous form. However, for correct usage of FOS, it is necessary to have a reliable susceptibility testing method suitable for routine practice and robust interpretation criteria. Results: The results were interpreted according to 2023 interpretation criteria provided by the European Committee on Antimicrobial Susceptibility Testing (EUCAST). DTR Gram-negatives were more likely to be resistant to FOS (45% in Enterobacterales and 20% in P. aeruginosa) than non-DTR (10% and 6.7%, resp.). All isolates of S. aureus were susceptible to FOS. In Gram-negatives, all agreement values were unacceptable. Etest® performed better in the DTR cohort (categorical agreement, CA, 80%) than in the non-DTR cohort (CA 45.7%). There were no very major errors (VREs) observed in P. aeruginosa. S. aureus had surprisingly low essential agreement (EA) rates (53% for MRSA and 47% for MSSA) for Etest®, but categorical agreement was 100%. Methods: A total of 130 bacterial isolates were tested and compared using the disc diffusion method (DD) and gradient strip method (Etest®) with the reference method (agar dilution, AD). The spectrum of isolates tested was as follows: 40 Enterobacterales (20 DTR vs. 20 non-DTR), 30 Pseudomonas aeruginosa (15 DTR vs. 15 non-DTR), and 60 Staphylococcus aureus (30 methicillin-susceptible, MSSA, vs. 30 methicillin-resistant, MRSA). Conclusions: Neither one of the tested methods was identified as a suitable alternative to AD. It would be beneficial to define more interpretation criteria, at least in some instances.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kroneislová, Gabriela $u Clinical Microbiology and ATB Centre, General University Hospital, 128 08 Prague, Czech Republic $1 https://orcid.org/0009000536075498
700    1_
$a Kroneisl, Marie $u Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, 9700 Groningen, The Netherlands $u Department of Surgery, University Hospital Bulovka, 180 00 Prague, Czech Republic $1 https://orcid.org/0009000904091193
700    1_
$a Adámková, Václava $u Clinical Microbiology and ATB Centre, General University Hospital, 128 08 Prague, Czech Republic $1 https://orcid.org/0000000276295365 $7 xx0070151
773    0_
$w MED00195446 $t Antibiotics (Basel) $x 2079-6382 $g Roč. 13, č. 11 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39596744 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250117 $b ABA008
991    __
$a 20250123102015 $b ABA008
999    __
$a ok $b bmc $g 2254498 $s 1238203
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 13 $c 11 $e 20241105 $i 2079-6382 $m Antibiotics (Basel) $n Antibiotics (Basel) $x MED00195446
GRA    __
$a MH CZ - DRO - VFN00064165 $p Ministry of Health, Czech Republic
LZP    __
$a Pubmed-20250117

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...